[Composition] Each 0.5mL of reconstituted vaccine contains
- **Active Ingredients:**
  - Live, attenuated varicella-zoster virus (in-house) – 2,400 PFU (Virus strain: Oka/SK, Cell line: MRC-5)
- **Excipients (Stabilizers):**
  - Sucrose (Ph. Eur.) – 25.00 mg
  - Hydrolyzed gelatin (NF) – 12.50 mg
  - Urea (Ph. Eur.) – 1.20 mg
  - Monosodium glutamate (NF) – 0.55 mg
  - Disodium edetate (Ph. Eur.) – 0.25 mg
  - L-cysteine (NF) – 0.25 mg
  - Glycine (Ph. Eur.) – 2.50 mg
- **Other Excipients:**
  - Sodium dihydrogen phosphate dihydrate, Disodium phosphate dodecahydrate, Sodium chloride, Potassium chloride, Sodium hydroxide
- **Each diluent contains:**
  - Water for injections (Ph. Eur.) – 0.7 mL

[Appearance]
Lyophilized white crystalline pellet in a clear colorless vial
Colorless or pale yellow liquid in the vial when reconstituted to a suspension

[Indications]
Prevention of varicella in children 12 months to 12 years of age

[Dosage and Administration]
FOR SUBCUTANEOUS ADMINISTRATION ONLY
Total volume (approximately 0.5 mL) of reconstituted vaccine is administered as a single dose subcutaneously into the outer aspect of the upper arm (deltoid region).
Do not administer this product intravenously, intramuscularly or intradermally.

[Reconstitution and Administration instructions]
To reconstitute the vaccine, withdraw the total volume of provided diluent and inject all withdrawn diluent into the vial of lyophilized vaccine. Gently agitate to dissolve completely. Withdraw the entire contents into the syringe and inject the total volume (approximately 0.5 mL) of reconstituted vaccine as a single dose subcutaneously into the outer aspect of the upper arm (deltoid region). In order to minimize loss of potency, the vaccine should be administered immediately after reconstitution.
Discard the reconstituted vaccine, if not used within 30 minutes.

[Precautions for use]
1. Contraindications
   1) Individuals with a history of hypersensitivity reaction to gelatin or any other component in SKVaricella Inj.
   2) Individuals with a history of anaphylactic/anaphylactoid reaction to neomycin (trace amount of neomycin is present in the reconstituted vaccine)
   3) Individuals with primary and acquired immunodeficiency states due to conditions such as acute and chronic leukemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to HIV/AIDS; and cellular immune deficiencies
   4) Individuals on immunosuppressive therapy (SKVaricella Inj. may cause disseminated diseases in individuals with immunodeficiency or on immunosuppressive therapy, as the vaccine is live, attenuated varicella virus vaccine)
   5) Individuals with untreated active tuberculosis
   6) Pregnant women or women of child-bearing potential (refer to 5. Use in pregnancy and lactation)
   7) Individuals with febrile respiratory disease or other febrile infections
2. Adverse Reactions
   1) Safety of SKVaricella Inj. was evaluated in 365 subjects aged 12 months to 12 years and 167 subjects (45.75%) experienced adverse drug reactions.
   2) Local reaction: Injection site pain/tenderness, erythema/redness, and induration/edema may occur.
   3) Systemic reaction: Fever, whining/irritation, sleepiness/feeling drained and occasionally systemic reaction such as fatigue/malaise and headache may occur after vaccination.
      1) Solicited adverse drug reactions (local and systemic reactions) after vaccination of SKVaricella Inj. are summarized in below table.

<table>
<thead>
<tr>
<th>Local reaction</th>
<th>Phase II clinical trial N=114</th>
<th>Phase III clinical trial N=251</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain/tenderness</td>
<td>14.04%</td>
<td>20.32%</td>
</tr>
<tr>
<td>Erythema/redness</td>
<td>17.54%</td>
<td>32.67%</td>
</tr>
<tr>
<td>Induration/swelling</td>
<td>6.14%</td>
<td>15.54%</td>
</tr>
<tr>
<td>Fever</td>
<td>7.02%</td>
<td>7.97%</td>
</tr>
<tr>
<td>Somnolence/exhausted</td>
<td>5.26%</td>
<td>7.57%</td>
</tr>
<tr>
<td>Headache</td>
<td>1.75%</td>
<td>2.36%</td>
</tr>
<tr>
<td>Whining/irritation</td>
<td>11.40%</td>
<td>11.95%</td>
</tr>
<tr>
<td>Fatigue/malaise†</td>
<td>0.00%</td>
<td>12.90%</td>
</tr>
</tbody>
</table>

† Adverse drug reactions were reported as per the planned data collection system and collected for 7 days post-vaccination (N=365).
†† Fatigue/malaise was investigated for children aged 5 years and older (Phase II clinical trial N=69, Phase III clinical trial N=131).
3) Unsolicited adverse drug reactions were reported in 16 (4.38%) out of 365 subjects aged 12 months to 12 years during 42 days post-vaccination of SKVaricella Inj. The most frequently reported unsolicited adverse drug reaction was skin and subcutaneous tissue disorders with 7 subjects (1.92%) reporting 8 cases and followed by infections and infestations with 6 subjects (1.64%) reporting 6 cases. With regard to the outcomes of adverse drug reactions, all subjects were recovered without sequelae. Adverse drug reactions occasionally observed (≥0.1% and <5%) are shown below.
   - Gastrointestinal disorders: Vomiting, diarrhea
   - Infections and Infestations: Gastroenteritis, nasopharyngitis, upper respiratory tract infection
   - General disorders and administration site conditions: Vaccination site erythema
   - Metabolism and nutrition disorder: Decreased appetite
   - Skin and subcutaneous tissue disorders: Erythema, rash, rash vesicular
3) 7 serious adverse events occurred within 26 weeks post-vaccination in 6 subjects (1.64%) out of 365 subjects (2 cases of bronchitis, 1 case of otitis media acute, 1 case of pneumonia, 1 case of upper respiratory tract infection, 1 case of pneumonia respiratory syncytial viral, and 1 case of thermal burn). All of these serious adverse events were confirmed to be not related to SKVaricella Inj., which were reported in phase III clinical trial.
   4) Varicella-like rashes were reported in 6 subjects (1.64%) out of 365 subjects with 6 cases within 42 days post-vaccination, which were reported in phase III clinical trial. Among the cases of varicella-like rash occurred within 42 days post-vaccination in the phase III clinical trial, 5 cases in 5 subjects were generalized varicella-like rashes and 1 case in 1 subject was injection-site varicella-like rash. In regard to 4 cases of generalized varicella-like rash and 1 case of injection-site varicella-like rash, samples from the lesion of subjects were collected and polymerase chain reaction (PCR) assay was conducted. As a result, varicella-zoster virus was identified in 5 cases, but the virus type (wild type or Oka/SK strain) could not be specified. 2 cases of generalized varicella-like rashes were confirmed to be not related to SKVaricella Inj., and it was determined that a causal relationship between 3 cases of generalized varicella-like rashes and 1 case of injection-site varicella-like rash and SKVaricella Inj. could not be ruled out.

3. General precautions
1) The duration of protection against varicella infection after vaccination with SKVaricella Inj. is unknown.
2) Effectiveness of re-vaccination has not been evaluated. The need for booster doses is not defined.
3) As with other vaccines, vaccination with SKVaricella Inj. does not result in protection of all vaccine recipients.
4) As with other vaccines, anaphylactic/anaphylactoid reaction might occur with SKVaricella Inj. Adequate treatment provisions, including epinephrine injection (1:1,000), should be available for immediate use.
5) Deferral of vaccination should be considered in acute illness (e.g., fever > 38.0°C).
6) After blood or plasma transfusion, or administration of immune globulin or varicella-zoster
   immune globulin, SKYV/varicella Inj. should be vaccinated with the minimum interval (3 to 11
   months), depending on the type and dose of blood or immunoglobulin.
7) SKYV/varicella Inj. should not be concomitantly with immune globulin including varicella-
   zoster immune globulin. Also, any immune globulin including varicella-zoster immune globulin
   should not be given for 2 months thereafter unless its use outweighs the benefit of vaccination.
8) Since Reye syndrome has been reported after the use of salicylates in the case of wild-type
   varicella infection, the vaccine recipients avoid the use of salicylates for 6 weeks post-vaccination.
9) Transmission of the vaccine virus has not been reported from SKYV/varicella Inj. clinical studies.
   However, it has been confirmed at post-marketing of other varicella vaccine that transmission of
   vaccine virus may occur rarely between healthy vaccinees who develop a varicella-like rash and
   healthy susceptible contacts and transmission of vaccine virus from vaccinees who do not develop a
   varicella-like rash has also been reported. Therefore, vaccine recipients should attempt to avoid,
   whenever possible, close association with susceptible high-risk individuals for up to 6 weeks. In
   circumstances where contact with high-risk individuals is unavoidable, the potential risk of
   transmission of vaccine virus should be weighed against the risk of acquiring and transmitting wild-
   type varicella virus. Susceptible high-risk individuals are as follows:
   * Immunosuppressed individuals
   * Pregnant women without documented history of chickenpox or laboratory evidence of prior
     infection
   * Newborns infants of mothers without documented history of chickenpox or laboratory evidence
     of prior infection

4. Interactions
   1) Refer to 3. General precautions for immune globulin, salicylates and transfusion.
   2) No data are available on the concomitant administration of the varicella vaccine with other vaccines.
      However, WHO recommends that varicella vaccine can be administered concomitantly with other
      vaccines included in the routine childhood vaccination programme. Unless given together with other
      live viral vaccines (measles, MR, MMR), it should be administered at a minimum interval of 28 days.

5. Use in pregnancy and lactation
   1) SKYV/varicella Inj. should not be administered to pregnant women. Wild-type varicella
      (natural infection) is known to sometimes cause fetal harm. Furthermore, pregnancy
      should be avoided for 3 months following vaccination. Safety of SKYV/varicella Inj. has
      not been evaluated in pregnant women. Direct and/or indirect adverse effect related to
      reproductive and developmental toxicity has not been observed in animal studies.
      (refer to 4. Contraindications)
   2) It is not known whether live attenuated varicella virus is excreted in human milk. However,
      because some viruses are excreted in human milk, caution should be exercised if SKYV/varicella
      Inj. is administered to nursing mothers.

6. Pediatric Use
   Since the safety and efficacy of the vaccine for infants less than 12 months of age has not been
   established, SKYV/varicella Inj. is not administered to infants less than 12 months of age.

7. Geriatric Use
   SKYV/varicella Inj. is not used in adults including elderly for the prevention of varicella.

8. Description
   SKYV/varicella Inj. is a preparation of the Oka/SL strain of live, attenuated varicella virus
   propagated in human diploid cells (MRC-5). SKYV/varicella Inj. might contain residual
   components of MRC-5 cells, including DNA and protein and trace quantities of neomycin.

9. Precautions for administration
   1) SKYV/varicella Inj. should be stored in the refrigerator and reconstituted immediately upon removal
      from the refrigerator. The vaccine should be used immediately after reconstitution.
      Do not freeze reconstituted vaccine.
   2) A separate sterile syringe and needle should be used for each injection to prevent transmission of
      infectious diseases. The used needles should be discarded appropriately to prevent reuse.

10. Precautions for storage and handling
    1) It should be stored in the original package to eliminate the cause of accidents or maintain the
        quality.
    2) It must not be mixed with other medicinal products in one syringe.

11. Information for professionals
    1) Pharmacological information
       SKYV/varicella Inj. is a live attenuated varicella-zoster virus vaccine (Oka/SL strain) inducing an
       immune response to varicella infection.
    2) Clinical trial information
       Efficacy (Immunogenicity) of SKYV/varicella Inj. was assessed with a multi-national, randomized,
       double-blind, active controlled, parallel clinical trial in healthy children 12 months to 12 years of age.
       The primary immunogenicity analysis was performed for 458 subjects in per protocol set (PPS) and
       non-inferiority in seroconversion rate was proven by fluorescent antibody to membrane antigen
       (FAMA) assay. FAMA assay results in phase III clinical trial are presented as below table.

<table>
<thead>
<tr>
<th></th>
<th>SKYV/varicella Inj. (N=228)</th>
<th>Comparator (N=230)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>GMT ± GSD</td>
<td>1.37 ± 2.62</td>
</tr>
<tr>
<td>95% CI of GMT</td>
<td>[1.21, 1.55]</td>
<td>[1.11, 1.33]</td>
</tr>
<tr>
<td>6 weeks post-vaccination</td>
<td>GMT ± GSD</td>
<td>103.15 ± 2.87</td>
</tr>
<tr>
<td>95% CI of GMT</td>
<td>[89.89, 118.36]</td>
<td>[46.39, 63.38]</td>
</tr>
<tr>
<td>6 weeks post-vaccination</td>
<td>GMR ± GSD</td>
<td>75.42 ± 3.77</td>
</tr>
<tr>
<td>95% CI of GMR</td>
<td>[63.42, 89.69]</td>
<td>[37.63, 52.81]</td>
</tr>
<tr>
<td>Seroconversion rate</td>
<td>% (M/F)</td>
<td>99.53 [211/212]</td>
</tr>
<tr>
<td>95% CI of seroconversion rate</td>
<td>[97.40, 99.99]</td>
<td>[92.99, 98.42]</td>
</tr>
<tr>
<td>Difference of rates between two vaccines</td>
<td>3.15</td>
<td></td>
</tr>
<tr>
<td>95% CI of difference of rates between two vaccines</td>
<td>[0.52, 5.78]</td>
<td></td>
</tr>
</tbody>
</table>

3) Non-clinical information
   The results from safety pharmacology studies (cardiovascular, respiratory and central nervous
   systems), single and repeated dose toxicity studies, and reproductive and developmental toxicity
   studies showed no potential adverse effects in humans.

[Storage]
   Keep refrigerated at 2°C to 8°C in a hermetic container away from light.
   Both lyophilized and reconstituted vaccine should be protected from light.

[Expiration date] As marked separately on the primary container.

[Packaging units]
1) A box of 5 lyophilized vaccine vials and 5 diluent vials
2) A box of 10 lyophilized vaccine vials and a box of 10 diluent vials

The Vaccine Vial Monitors (VVM) are on the label of SKYV/varicella Inj. attached to the vial body. The color
dot which appears on the label of the vial is a VVM. This is a temperature-sensitive dot that provides an
indication of the cumulative heat to which the vial has been exposed. In the event the user when
exposure to heat is likely to have degraded the vaccine beyond an acceptable level.

- Inner square lighter than outer circle
  - If the expiry date has not been passed, USE the vaccine.
- At a later time, inner square still lighter than outer circle
  - If the expiry date has not been passed, USE the vaccine.
- Beyond the discard point: Inner square darken than outer circle
  - DO NOT use the vaccine.

The interpretation of the VVM is simple. Focus on the central square. Its color will change progressively.
As long as the color of this square is lighter than the color of the circle, then the vaccine can be used. As
soon as the color of the central square is the same color as the circle or of a darker than the circle, then
the vial should be discarded.